Search clinical trials for: 8H9

Total 180 results

Peking Union Medical College Hospital

Not yet recruiting

Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Bone Metastases | Thyroid Neoplasm Follicular

China
Auspex Pharmaceuticals, Inc.

Completed

Alternatives for Reducing Chorea in Huntington Disease (ARC-HD)

Chorea Associated With Huntington Disease

United States, Australia, Canada
Prokarium Ltd
Simbec Research

Completed

Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine

Enteric Fever

United Kingdom
Medical University of Graz
Austrian Science Fund (FWF)

Completed

Influence of Probiotics on Infections in Cirrhosis (PIC)

Liver Cirrhosis

Austria
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Cystic Fibrosis

Netherlands
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Acute Myeloid Leukemia (AML) | Acute Lymphocytic Leukemia (ALL)

United States
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

Cystic Fibrosis

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Mexico
AstraZeneca
ImaginAb, Inc.

Terminated

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Colorectal Cancer

United States, Canada
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, Australia, Brazil, Czech Republic, Russian Federation, Singapore
Oslo University Hospital
Uppsala University Hospital

Completed

Burst Spinal Cord Stimulation for Neuropathic Pain.

Lower Back Pain | Radiculopathy | Peripheral Neuropathic Pain

Norway, Sweden
ImaginAb, Inc.
University of Hull

Recruiting

CD8 Minibody Repeatability Study (PRETZCEL)

Melanoma | Renal Cell Carcinoma

United Kingdom
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
Calithera Biosciences, Inc

Completed

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (CANTATA)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States, United Kingdom, Australia, France, Italy, Germany, Spain, New Zealand
Wenzhou Medical University

Recruiting

Comparison of Outcomes With Multifocal Intraocular Lenses (COMIL)

Cataract

China
Alloksys Life Sciences B.V.
Aix Scientifics

Completed

Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery (APPIRED-II)

Inflammation

Netherlands
University Medical Center Groningen

Completed

89Zr-AMG211 PET Imaging Study

Advanced Gastrointestinal Cancer

Netherlands
Institute of Skin and Product Evaluation, Italy

Active, not recruiting

Clinical Benefit of M89PB in Subjects With Rosacea Associated With Erythema and Sensitive Skin

Rosacea | Sensitive Skin

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2

United States
Anchiano Therapeutics Israel Ltd.

Terminated

Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC-BC-819)

Pancreas, Adenocarcinoma

Israel, United States
Genexine, Inc.

Completed

A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9

Adult Growth Hormone Deficiency

Korea, Republic of
University of California, San Francisco
amfAR, The Foundation for AIDS Research

Recruiting

PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)

HIV-1-infection

United States
Radboud University Medical Center

Completed

Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma

Renal Cell Carcinoma

Netherlands
University of Alabama at Birmingham

Recruiting

Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

Multiple Sclerosis | Healthy | Fibromyalgia | Chronic Fatigue Syndrome

United States
Buckinghamshire Healthcare NHS Trust
National Institute for Health Research, United Kingdom; Oxford Clinical Trials...

Completed

Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) (PReSuTINeB)

Neurogenic Bladder | Antibiotic Resistance | UTI

United Kingdom
David Bajor

Active, not recruiting

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Colorectal Cancer | Rectal Cancer | Solid Tumor | Colon Cancer

United States
Anchiano Therapeutics Israel Ltd.

Completed

Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Transitional Cell Carcinoma of Bladder

Israel
Genexine, Inc.

Completed

Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency

Growth Hormone Deficiency

Ukraine
European Organisation for Research and Treatment...

Completed

Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases

Prostate Cancer | Metastatic Cancer

Netherlands, Denmark, Belgium, Poland, Switzerland, United Kingdom, Italy, Russian Federation, Portugal
Abbott

Terminated

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Liver Diseases | Digestive System Diseases | Neoplasms | Neoplasms by Histologic Type | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Hepatocellular Carcinoma Non-resectable | Hepatocellular Carcinoma...

United States, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Czech Republic, Denmark, Egypt, France, Germany, Greece, Hong Kong, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Norway, Puerto... and more
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Cystic Fibrosis | Advanced Lung Disease

United States
Abbott
Genentech, Inc.

Withdrawn

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Solid Tumors
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States
Tallikut Pharmaceuticals, Inc.

Completed

Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy

Atherosclerosis

Italy
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Multiple Myeloma | Non-Hodgkin's Lymphoma (NHL) | Waldenstrom's Macroglobulinemia (WM) | Other B-cell NHL Subtypes, Including WM | T-cell NHL

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Australia, Denmark, Canada, Sweden
Abbott

Completed

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)

Solid Tumors

United States
Vertex Pharmaceuticals Incorporated

Completed

Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Massachusetts General Hospital
Pfizer; Prostate Cancer Foundation; Calithera Biosciences, Inc

Not yet recruiting

Telaglenastat + Talazoparib In Prostate Cancer

Prostate Cancer Metastatic

United States
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
Alberta Health services
Amersham Health; The Prostate Cancer Research Foundation of Canada

Completed

A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer

Bone Metastases | Hormone Refractory Prostate Cancer

Canada
Calithera Biosciences, Inc

Completed

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) (ENTRATA)

Clear Cell Renal Cell Carcinoma

United States
Vertex Pharmaceuticals Incorporated

Completed

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Calithera Biosciences, Inc

Terminated

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Clear Cell Renal Cell Carcinoma (ccRCC)

United States
Hannover Medical School
Heidelberg University; University of Giessen

Completed

ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor (OrkambiFacts)

Cystic Fibrosis

Germany
University of Sydney
University of Pennsylvania; University of California, San Diego; University of... and other collaborators

Completed

Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis (NeOProM)

Infant, Newborn, Diseases | Infant, Premature, Diseases | Retinopathy of Prematurity | Bronchopulmonary Dysplasia | Infant, Very Low Birth Weight

Australia
Adlai Nortye Biopharma Co., Ltd.
Merck Sharp & Dohme LLC

Active, not recruiting

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Cervical Cancer | Triple-negative Breast Cancer | NSCLC, Squamous or Non-Squamous | Urothelial Carcinoma of the Bladder | Microsatellite Stable (MSS) Colorectal Cancer (CRC)

United States, France

Search clinical trials for: 8H9

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations